Hashimoto S, Kitahara T, Arimoto T, Kamada T, Shirato H, Nishioka T, Nojima T
Department of Radiology, Hokkaido University, School of Medicine.
Nihon Igaku Hoshasen Gakkai Zasshi. 1993 Jun 25;53(6):679-87.
We studied 30 patients with early stage malignant lymphomas involving the nasal cavity and/or paranasal sinus who were treated between 1972 to 1991 in Hokkaido University Hospital. The mean age of the patients was 60.6 yr, and the male-to-female ratio was 2.6. The predominant histologic type was diffuse large cell type (n = 23). Treatment policy differed depending on time: radiotherapy (RT) alone between 1972 and 1980 (n = 15), RT followed by modified CVP or CHOP between 1981 and 1988 (n = 10) and BACOP followed by RT between 1989 and 1991 (n = 5). Overall five-year survival was 53%. Better survival was observed in patients with B-cell type (72%), smaller mass (tumor limited to the unilateral nasal cavity or paranasal sinus) (76%), and patients who were treated with combination chemotherapy (BACOP) followed by RT (100%). Eleven patients experienced recurrence. Four of nine local recurrences were in patients with T-cell lymphoma. CNS relapse was observed in three patients with T-cell lymphoma. We conclude that T-cell lymphoma arising at the nasal cavity and/or paranasal sinus needs careful follow-up for its high frequency of local and CNS relapse. More intensive treatment such as prophylactic whole brain RT, intrathecal administration of MTX or third generation chemotherapy (e.g. MACOP-B) might improve survival in these patients.
我们研究了1972年至1991年期间在北海道大学医院接受治疗的30例早期鼻腔和/或鼻窦恶性淋巴瘤患者。患者的平均年龄为60.6岁,男女比例为2.6。主要组织学类型为弥漫大细胞型(n = 23)。治疗策略因时间而异:1972年至1980年期间单纯放疗(RT)(n = 15),1981年至1988年期间放疗后采用改良CVP或CHOP方案(n = 10),1989年至1991年期间BACOP方案后行放疗(n = 5)。总体五年生存率为53%。B细胞型患者(72%)、肿块较小(肿瘤局限于单侧鼻腔或鼻窦)的患者(76%)以及接受联合化疗(BACOP)后行放疗的患者(100%)生存率更高。11例患者出现复发。9例局部复发患者中有4例为T细胞淋巴瘤患者。3例T细胞淋巴瘤患者出现中枢神经系统复发。我们得出结论,鼻腔和/或鼻窦发生的T细胞淋巴瘤因其局部和中枢神经系统复发频率高,需要密切随访。更强化的治疗,如预防性全脑放疗、鞘内注射甲氨蝶呤或第三代化疗(如MACOP - B)可能会提高这些患者的生存率。